Outlook Therapeutics’ (OTLK) “Neutral” Rating Reiterated at Chardan Capital

Outlook Therapeutics (NASDAQ:OTLK)‘s stock had its “neutral” rating reissued by research analysts at Chardan Capital in a note issued to investors on Monday,Benzinga reports.

Several other equities analysts have also commented on the stock. Ascendiant Capital Markets decreased their target price on shares of Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Outlook Therapeutics in a research report on Friday. Finally, BTIG Research lowered their price objective on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research report on Friday. One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Outlook Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.34.

Outlook Therapeutics Stock Performance

NASDAQ:OTLK opened at $2.05 on Monday. The company has a market cap of $48.50 million, a price-to-earnings ratio of -0.19 and a beta of 0.62. Outlook Therapeutics has a fifty-two week low of $0.87 and a fifty-two week high of $12.85. The stock has a fifty day moving average price of $5.29 and a 200-day moving average price of $6.70.

Insider Buying and Selling at Outlook Therapeutics

In other news, CFO Lawrence A. Kenyon bought 5,000 shares of the stock in a transaction on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the acquisition, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. This trade represents a 528.54 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.40% of the company’s stock.

Institutional Trading of Outlook Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Christensen King & Associates Investment Services Inc. bought a new position in Outlook Therapeutics in the 3rd quarter valued at approximately $55,000. AQR Capital Management LLC acquired a new stake in Outlook Therapeutics in the second quarter valued at $75,000. Barclays PLC increased its holdings in Outlook Therapeutics by 677.4% in the third quarter. Barclays PLC now owns 20,943 shares of the company’s stock valued at $111,000 after purchasing an additional 18,249 shares during the period. XTX Topco Ltd bought a new position in Outlook Therapeutics during the 3rd quarter worth $199,000. Finally, Squarepoint Ops LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth about $232,000. 11.20% of the stock is currently owned by institutional investors.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.